Liberpharma is engaged in the discovery and development of novel, small molecules for the treatment of diseases trough modification of lead compounds. Characterization techniques for elucidating the ligand-target structure include x-ray crystallography and nuclear magnetic resonance spectroscopy Lead compounds will be modified using high resolution computer modeling, medicinal- and computational[computing the energy of a particular molecular structure] chemistry Combinatorial chemistry will be used to produce the intended novel, highly specific small molecule compounds,needed for therapeutic benefits. First step is creating a low Ki value ,followed by adjusting for cell permeability, solubility [more hydrophile,lowering Log p],plasma stability,ADME, check Herg,Cytochrom etc [anti-gen]and toxicity The initial leads are proprietary chemical compounds